Interpreting 7-Year Valve Durability in PARTNER 3 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessing Seven-Year Valve Durability in the PARTNER 3 Trial

  • By

  • Dritan Useini

  • November 1, 2026

Share

  • 1

    The PARTNER 3 analysis compared the SAPIEN 3 valve with a heterogeneous group of surgical bioprostheses.

  • 2

    Surgical bioprostheses vary in structural valve deterioration, hemodynamic performance, and durability.

  • 3

    Transcatheter valve platforms also differ in long-term performance, and PARTNER analyses found different structural valve deterioration rates for SAPIEN XT and SAPIEN 3.

  • 4

    Comparing one transcatheter platform with pooled surgical valves complicates attribution of durability differences to the procedure rather than the specific valves.

  • 5

    The authors call for head-to-head comparisons of individual valve platforms and recognition of mechanical prostheses as an option for selected young patients willing and able to take lifelong anticoag

Original Source(s)

Related Content